Cargando…
Cost-Effectiveness of Treatment Strategies with Biologics in Accordance with Treatment Guidelines for Ankylosing Spondylitis: A Patient-Level Model
BACKGROUND: Ankylosing spondylitis (AS) is a form of rheumatic disease caused by chronic inflammation of the axial skeleton. Patients with AS experience significant functional limitations and reduced quality of life. Consequently, AS imposes a substantial economic burden on society due to productivi...
Autores principales: | Le, Quang A., Kang, Jenny H., Lee, Sun, Delevry, Dimittri |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academy of Managed Care Pharmacy
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391255/ https://www.ncbi.nlm.nih.gov/pubmed/32996395 http://dx.doi.org/10.18553/jmcp.2020.26.10.1219 |
Ejemplares similares
-
The Authors Respond
por: Le, Quang A., et al.
Publicado: (2020) -
Cost-effectiveness of secukinumab compared to other biologics in the treatment of ankylosing spondylitis in Finland
por: Purmonen, Timo, et al.
Publicado: (2019) -
Update on the treatment of ankylosing spondylitis
por: Maksymowych, Walter P
Publicado: (2007) -
Infliximab in the treatment of ankylosing spondylitis
por: Grainger, Rebecca, et al.
Publicado: (2007) -
Medical Treatment of Ankylosing Spondylitis
por: Moon, Kyoung-Ho, et al.
Publicado: (2014)